Haleon plc (NYSE:HLN) Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. reduced its stake in shares of Haleon plc (NYSE:HLN) by 2.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 179,896 shares of the company’s stock after selling 4,629 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Haleon were worth $1,716,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sierra Ocean LLC purchased a new stake in Haleon during the fourth quarter worth about $26,000. Versant Capital Management Inc grew its holdings in shares of Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after acquiring an additional 3,348 shares during the period. Toronto Dominion Bank increased its stake in Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after purchasing an additional 3,470 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in Haleon during the fourth quarter worth $35,000. Finally, Spire Wealth Management purchased a new stake in Haleon during the fourth quarter worth $39,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Stock Down 1.0 %

Shares of NYSE HLN opened at $10.29 on Friday. The firm has a market cap of $46.56 billion, a P/E ratio of 30.25, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a 1 year low of $7.99 and a 1 year high of $10.80. The firm’s 50 day moving average price is $9.84 and its 200 day moving average price is $9.88.

Haleon (NYSE:HLN) last posted its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, sell-side analysts anticipate that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The business also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This represents a dividend yield of 1.6%. This is an increase from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio is currently 58.97%.

Analysts Set New Price Targets

HLN has been the subject of several research reports. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. HSBC restated a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Finally, Hsbc Global Res downgraded Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Six equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.